The Managed Care Review Board™ – Analyzing the Latest Advancements with Oral Anticoagulation Therapy
DISTINGUISHED FACULTY CONTRIBUTORS | ||||||||||||
|
||||||||||||
|
||||||||||||
TARGET AUDIENCE
STATEMENT OF NEED/PROGRAM OVERVIEW
An enhanced understanding of the pathophysiology of thromboembolic disorders has facilitated the development of novel therapies including factor Xa inhibitors and DTIs for preventing stroke and thromboembolism in at-risk patients. For managed care professionals and affiliated providers, enhanced competence is needed to assess and compare the three newly approved anticoagulant options. With the expected approval of a fourth such agent in 2014, the originators of the evidence-based treatment recommendations that guide clinical practice and therapeutic selection are challenged to define the roles of these new agents relative to warfarin. The uncertainty that providers experience as these are introduced and as treatment guidelines are revamped clearly justifies the need for robust educational efforts to inform managed care practitioners and decision makers of the key features of these new agents: mechanism of action, efficacy, safety, dosing, and monitoring.
By addressing practice gaps and reviewing the most current clinical and cost-effectiveness data available, this educational activity will help guide the audience to implement appropriate therapeutic and benefit-management strategies to reduce the risk of stroke and thromboembolism, two clinically-significant and costly diagnoses. Thought leaders from both clinical and managed care perspectives will recommend innovative strategies and practical methods to improve treatment success for patients who require anticoagulation to prevent stroke and systemic thromboembolism, while reducing the cost complexities associated with these pharmacologic advancements.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
ACCREDITATION
Physician Continuing Education
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Impact Education, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this monograph for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Pharmacy Continuing Education
Pharmacy Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Credit Designation
This program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Activity # 0797-9999-14-129-H04-P. This program is designated for up to 1.1 contact hours (0.11 CEUs) of the continuing pharmacy education credit.
Type of Activity
Knowledge
Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor within 4 weeks.
Nursing Continuing Education
Accreditation Statement
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation
A maximum of 1.1 contact hours may be earned for successful completion of this activity.
A statement of credit will be issued only upon receipt of a completed activity evaluation form.
DISCLOSURE OF CONFLICTS OF INTEREST
The Annenberg Center for Health Sciences at Eisenhower assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for Health Sciences at Eisenhower for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter | Reported Financial Relationship |
Joseph E. Biskupiak, PhD, MBA | Consulting Fees: Pfizer, Inc., Boehringer Ingelheim, Bristol-Myers Squibb Contracted Research: Pfizer, Inc., Boehringer Ingelheim, Bristol-Myers Squibb |
Chris Cannon, MD, FACC | Consulting Fees: Bristol-Myers Squibb, CSL Behring, Essentialis, Inc., GlaxoSmithKline, Lipimedix, Merck & Co., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Sanofi-Aventis Grants: Accumetrics, Arisaph Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Merck & Co., Takeda Pharmaceutical Company Limited |
Jeffrey D. Dunn, PharmD, MBA | Consulting Fees: Boehringer Ingelheim, Daiichi Sankyo, Inc., Pfizer, Inc. |
John Fox, MD | No financial interest/relationships relating to the topic of this activity |
The planners and managers reported the following financial relationships or relationships to products of devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner/Manager | Reported Financial Relationship |
Steven Casebeer, MBA | No financial interest/relationships relating to the topic of this activity |
Keith Engelke, PhD | No financial interest/relationships relating to the topic of this activity |
The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. | |
Charles E. Willis, Director of Continuing Education (Annenberg Center for Health Sciences at Eisenhower), consults for Pfizer |
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period October 10, 2014 through April 29, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor within 4 weeks.
MEDIA
Monograph
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center for Health Sciences at Eisenhower, Postgraduate Institute for Medicine (PIM), Impact Education, LLC (IE), and commercial grantors do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower, PIM, IE, and commercial grantors. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medication, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities
FEE INFORMATION
There is no fee for this educational activity.